Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy
- 107 Downloads
There is consensus that patients should be treated with antiplatelet agents, beta-blockers, ACE-inhibitors/ARBs, and lipid lowering drugs for secondary prevention after acute myocardial infarction (AMI), but this evidence-based pharmacotherapy is underutilized. A quality improvement program was conducted in the Austrian county of Burgenland to emphasize the importance of cardiovascular drug therapy at hospital discharge in patients with AMI. In this prospective cohort study 250 members of a regional health insurance company, Burgenländische Gebietskrankenkasse (BGKK), with AMI during the year 2003 were identified using BGKK database. Discharge prescriptions and pharmacy reimbursement data of all included patients were determined. Overall prescription rate for patients discharged from hospital after AMI (n = 207) was 86% for platelet aggregation inhibitors, 77% for ACE-inhibitors or ARBs, 72% for beta-blockers, and 68% for a lipid lowering agent including statins. The all-cause mortality rate during a mean follow-up period of 552 days was 20%. Hazard ratio (HR) for death of patients with maximum 2 medications vs. those receiving 3 or 4 medications was 2.23 (95% CI: 1.19–4.18; p = 0.012). These data demonstrate that use of evidence-based drug treatment for prevention of mortality in patients with AMI is associated with risk reduction and survival benefit. Continuous quality improvement initiatives serve to improve outcome after AMI.
Keywordsacute myocardial infarction, survival, evidence-based medication, epidemiology
We would like to thank all participating centres and physicians for their contribution and support.
- 4.Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. (1999) Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353: 1547–557CrossRefPubMedGoogle Scholar
- 5.STATISTIK Austria- Jahrbuch der Gesundheitsstatistik 2004. Available at www.statistik.at/neuerscheinungen//download/2006/gesundheit 2004Google Scholar
- 7.Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Br Med J 316: 1337–343Google Scholar
- 8.Dickstein K, Kjekshus J. (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360: 752–60CrossRefPubMedGoogle Scholar
- 9.Freemantle N, Cleland J, Young P, Mason J, Harrison J. (1999) Beta Blockade after myocardial infarction: systematic review, meta regression analysis. Br Med J 318: 1730–737Google Scholar
- 10.Antman EM, Anbe DT, Armstrong PW, et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44: E1–E211CrossRefPubMedGoogle Scholar
- 14.Hasdai D, Behar S, Wallentin L, et al. (2002) A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23: 1190–201CrossRefPubMedGoogle Scholar